Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVACAST: Rivaroxaban versus low-molecular-weight heparin in lower limb trauma with casting
2023-509905-62-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Symptomatic venous thromboembolic events within 45 days. Planned start Apr 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-509905-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509905-62-00.